1-Cyclohexyl-5-methyl-2H-pyrazol-3-one | 2140305-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 1-Cyclohexyl-5-methyl-2H-pyrazol-3-one
• 英文别名: 2-cyclohexyl-3-methyl-1H-pyrazol-5-one
• CAS: 2140305-55-9
• 化学式: C₁₀H₁₆N₂O
• 分子量: 180.25
• InChiKey: LSLVBRVVVZKSPL-UHFFFAOYSA-N

物化性质

• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10011612B2

  公开（公告）日：2018-07-03

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供了包含式 I 或其药学上可接受的盐或组合物的补体因子 D 抑制剂的化合物、使用方法和制造工艺，其中 A 基上的 R12 或 R13 是芳基、杂芳基或杂环 (R32)。本文所述的因子 D 抑制剂可减少补体的过度活化。
• Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170066783A1

  公开（公告）日：2017-03-09

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
• ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20190211033A1

  公开（公告）日：2019-07-11

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.